{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:46:10Z","timestamp":1790469970680,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T00:00:00Z","timestamp":1533600000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014487","name":"Clovis Oncology","doi-asserted-by":"publisher","award":["Oncology"],"award-info":[{"award-number":["Oncology"]}],"id":[{"id":"10.13039\/100014487","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000032","name":"Institute of Infection and Immunity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.cllc.2018.07.008","type":"journal-article","created":{"date-parts":[[2018,8,6]],"date-time":"2018-08-06T21:06:58Z","timestamp":1533589618000},"page":"518-530.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor"],"prefix":"10.1016","volume":"19","author":[{"given":"Elena","family":"Helman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris A.","family":"Karlovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrin","family":"Despain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Karin","family":"Choquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander I.","family":"Spira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena A.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Ross","family":"Camidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Lanman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2018.07.008_bib1","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2018.07.008_bib2","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non\u2013small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2018.07.008_bib3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation\u2013positive non\u2013small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2018.07.008_bib4","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2018.07.008_bib5","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/JTO.0000000000000481","article-title":"Updated frequency of EGFR and KRAS mutations in nonsmall-cell lung cancer in Latin America: the Latin-American Consortium for the Investigation of Lung Cancer (CLICaP)","volume":"10","author":"Arrieta","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2018.07.008_bib6","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor\u2013resistant non\u2013small-cell lung cancer","volume":"372","author":"Janne","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2018.07.008_bib7","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2014.104","article-title":"Acquired resistance to TKIs in solid tumours: learning from lung cancer","volume":"11","author":"Camidge","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.cllc.2018.07.008_bib8","first-page":"67","article-title":"Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations\u2014a review","volume":"4","author":"Stewart","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cllc.2018.07.008_bib9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000443368","article-title":"Drug resistance to EGFR inhibitors in lung cancer","volume":"61","author":"Tetsu","year":"2016","journal-title":"Chemotherapy"},{"key":"10.1016\/j.cllc.2018.07.008_bib10","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum\u2013pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2018.07.008_bib11","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJMoa1413654","article-title":"Rociletinib in EGFR-mutated non\u2013small-cell lung cancer","volume":"372","author":"Sequist","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2018.07.008_bib12","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1056\/NEJMc1602688","article-title":"Update to rociletinib data with the RECIST confirmed response rate","volume":"374","author":"Sequist","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2018.07.008_bib13","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S1470-2045(16)30508-3","article-title":"Osimertinib for pretreated EGFR Thr790Met\u2013positive advanced non\u2013small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study","volume":"17","author":"Goss","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2018.07.008_bib14","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1158\/2159-8290.CD-15-0399","article-title":"Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor","volume":"5","author":"Piotrowska","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2018.07.008_bib15","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non\u2013small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.cllc.2018.07.008_bib16","doi-asserted-by":"crossref","first-page":"13513","DOI":"10.1038\/ncomms13513","article-title":"Corrigendum: circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients","volume":"7","author":"Chabon","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.cllc.2018.07.008_bib17","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1097\/JTO.0000000000000688","article-title":"Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor","volume":"10","author":"Kim","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2018.07.008_bib18","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1158\/1078-0432.CCR-15-1915","article-title":"Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors","volume":"22","author":"Ortiz-Cuaran","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2018.07.008_bib19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.lungcan.2016.05.015","article-title":"High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression","volume":"98","author":"Ou","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2018.07.008_bib20","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12885-016-2088-5","article-title":"Metastatic EML4-ALK fusion detected by circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: a case report","volume":"16","author":"Liang","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cllc.2018.07.008_bib21","doi-asserted-by":"crossref","first-page":"e0140712","DOI":"10.1371\/journal.pone.0140712","article-title":"Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA","volume":"10","author":"Lanman","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cllc.2018.07.008_bib22","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.jtho.2016.05.035","article-title":"A\u00a0highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma","volume":"11","author":"Reckamp","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2018.07.008_bib23","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.29089","article-title":"Clinical next-generation sequencing in patients with non\u2013small cell lung cancer","volume":"121","author":"Hagemann","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2018.07.008_bib24","doi-asserted-by":"crossref","first-page":"66880","DOI":"10.18632\/oncotarget.11801","article-title":"Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer","volume":"7","author":"Villaflor","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.cllc.2018.07.008_bib25","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1158\/1078-0432.CCR-16-1231","article-title":"Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA","volume":"22","author":"Thompson","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2018.07.008_bib26","doi-asserted-by":"crossref","first-page":"9364","DOI":"10.1158\/0008-5472.CAN-07-0605","article-title":"Serial assessment of human tumor burdens in mice by the analysis of circulating DNA","volume":"67","author":"Rago","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2018.07.008_bib27","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1158\/1078-0432.CCR-15-1260","article-title":"Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase I study of rociletinib (CO-1686)","volume":"22","author":"Karlovich","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2018.07.008_bib28","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.lungcan.2015.10.004","article-title":"EGFR mutation detection in ctDNA from\u00a0NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291","volume":"90","author":"Thress","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2018.07.008_bib29","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.3564","article-title":"Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas","volume":"48","author":"Campbell","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.cllc.2018.07.008_bib30","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1200\/JCO.2014.58.9325","article-title":"Expanded RAS: refining the patient population","volume":"33","author":"Atreya","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2018.07.008_bib31","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.gene.2016.06.053","article-title":"Comparison of plasma and tissue samples in epidermal growth factor receptor mutation by ARMS in advanced non\u2013small cell lung cancer","volume":"591","author":"Ma","year":"2016","journal-title":"Gene"},{"key":"10.1016\/j.cllc.2018.07.008_bib32","doi-asserted-by":"crossref","first-page":"e775","DOI":"10.1097\/MD.0000000000000775","article-title":"Blood as a substitute for tumor tissue in detecting EGFR mutations for guiding EGFR TKIs treatment of nonsmall cell lung cancer: a systematic review and meta-analysis","volume":"94","author":"Mao","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cllc.2018.07.008_bib33","first-page":"584","article-title":"Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non\u2013small cell lung cancer","volume":"4","author":"Bordi","year":"2015","journal-title":"Transl Lung Cancer Res"},{"issue":"suppl","key":"10.1016\/j.cllc.2018.07.008_bib34","first-page":"S386","article-title":"MA08.03 Osimertinib vs. platinum\u2013pemetrexed for T790M-mutation positive advanced NSCLC (AURA3): plasma ctDNA analysis","volume":"12","author":"Wu","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2018.07.008_bib35","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1200\/JCO.2016.66.7162","article-title":"Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non\u2013small-cell lung cancer","volume":"34","author":"Oxnard","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2018.07.008_bib36","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.cllc.2018.07.008_bib37","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature12912","article-title":"Discovery and saturation analysis of cancer genes across 21 tumor types","volume":"505","author":"Lawrence","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.cllc.2018.07.008_bib38","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/ng.2760","article-title":"Pan-cancer patterns of somatic copy number alteration","volume":"45","author":"Zack","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.cllc.2018.07.008_bib39","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/ng.3990","article-title":"Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers","volume":"49","author":"Blakely","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.cllc.2018.07.008_bib40","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1371\/journal.pmed.0020017","article-title":"KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med"},{"key":"10.1016\/j.cllc.2018.07.008_bib41","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/sj.bjc.6605534","article-title":"Activating K-Ras mutations outwith \u201chotspot\u201d codons in sporadic colorectal tumours\u2014implications for personalised cancer medicine","volume":"102","author":"Smith","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2018.07.008_bib42","doi-asserted-by":"crossref","first-page":"8535","DOI":"10.1038\/srep08535","article-title":"Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines","volume":"5","author":"Stolze","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.cllc.2018.07.008_bib43","doi-asserted-by":"crossref","first-page":"39028","DOI":"10.18632\/oncotarget.5494","article-title":"NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line","volume":"6","author":"Lee","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.cllc.2018.07.008_bib44","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.canlet.2015.05.013","article-title":"Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma","volume":"365","author":"Creancier","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.cllc.2018.07.008_bib45","first-page":"1457","article-title":"High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma","volume":"4","author":"Bongarzone","year":"1989","journal-title":"Oncogene"},{"key":"10.1016\/j.cllc.2018.07.008_bib46","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1006\/geno.1995.1100","article-title":"A\u00a0sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas","volume":"28","author":"Butti","year":"1995","journal-title":"Genomics"},{"key":"10.1016\/j.cllc.2018.07.008_bib47","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/ng.2938","article-title":"The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma","volume":"46","author":"Wu","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.cllc.2018.07.008_bib48","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/nm.3352","article-title":"Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer","volume":"19","author":"Vaishnavi","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.cllc.2018.07.008_bib49","doi-asserted-by":"crossref","first-page":"e000023","DOI":"10.1136\/esmoopen-2015-000023","article-title":"NTRK gene fusions as novel targets of cancer therapy across multiple tumour types","volume":"1","author":"Amatu","year":"2016","journal-title":"ESMO Open"},{"key":"10.1016\/j.cllc.2018.07.008_bib50","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.pharmthera.2017.02.006","article-title":"Targeting TRK family proteins in cancer","volume":"173","author":"Khotskaya","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.cllc.2018.07.008_bib51","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1158\/2159-8290.CD-14-0765","article-title":"TRKing down an old oncogene in a new era of targeted therapy","volume":"5","author":"Vaishnavi","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2018.07.008_bib52","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multi-targeted pan-TRK, ROS1, and ALK inhibitor entrectinib (RXDX-101): combined results from two phase 1 trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2018.07.008_bib53","doi-asserted-by":"crossref","first-page":"LBA2501","DOI":"10.1200\/JCO.2017.35.18_suppl.LBA2501","article-title":"The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers","volume":"35","author":"Hyman","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2018.07.008_bib54","doi-asserted-by":"crossref","first-page":"9020","DOI":"10.1200\/JCO.2017.35.15_suppl.9020","article-title":"MET amplification (amp) as a resistance mechanism to osimertinib","volume":"35","author":"Piotrowska","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2018.07.008_bib55","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1158\/1078-0432.CCR-17-3831","article-title":"Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies","volume":"24","author":"Odegaard","year":"2018","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573041830192X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573041830192X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:07:46Z","timestamp":1761505666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152573041830192X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S152573041830192X"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2018.07.008","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2018.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}